Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METATENSIN #4 vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing c GMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension
Hypertension
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
12-18 hours; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min)
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Reserpine: extensively metabolized in liver via unidentified pathways; Hydralazine: N-acetylation (polymorphic NAT2), also hydroxylation and glucuronidation; Hydrochlorothiazide: not significantly metabolized, excreted unchanged in urine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
95% bound to albumin and alpha-1-acid glycoprotein
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
0.5-1.0 L/kg; indicates moderate tissue distribution
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 60-80% (first-pass metabolism reduces from 100%)
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
No dosage adjustment required for renal impairment.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Severe hepatic impairment (Child-Pugh class C): Use with caution; reduce dose or prolong interval. Child-Pugh class A or B: No adjustment necessary.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not established; safety and efficacy in children have not been studied.
Not established; avoid use in children.
Elderly patients may be more sensitive to hypotensive effects; initiate at lower dose (1 tablet) and titrate carefully.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None.
None
Reserpine: mental depression, peptic ulcer, ulcerative colitis. Hydralazine: drug-induced lupus erythematosus, peripheral neuritis. Hydrochlorothiazide: electrolyte disturbances, hyperuricemia, acute angle-closure glaucoma, sulfonamide allergy cross-reactivity.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Reserpine: history of depression, active peptic ulcer, ulcerative colitis, pheochromocytoma, electroconvulsive therapy. Hydralazine: hypersensitivity, coronary artery disease, mitral valvular rheumatic heart disease. Hydrochlorothiazide: anuria, hypersensitivity to sulfonamide-derived drugs.
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-potassium foods (bananas, oranges, salt substitutes) due to risk of hyperkalemia with methyldopa. Limit sodium intake for antihypertensive effect. Alcohol may potentiate orthostatic hypotension and sedation.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
METATENSIN #4 (combination of hydrochlorothiazide 50 mg and methyldopa 250 mg per tablet) carries teratogenic risks primarily due to hydrochlorothiazide. First trimester: Thiazide diuretics are associated with a small increased risk of neural tube defects and cardiovascular anomalies; however, methyldopa is considered low risk for major malformations. Second trimester: Use may cause fetal electrolyte disturbances and thrombocytopenia. Third trimester: Thiazides can cause neonatal hypotension, hypoglycemia, bone marrow suppression, and volume depletion; methyldopa is associated with neonatal bradycardia and hypotension. Overall risk is considered moderate; alternative antihypertensives are preferred, especially in the first trimester.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Hydrochlorothiazide is excreted into breast milk in low concentrations (M/P ratio ~0.3), but its use may suppress lactation. Methyldopa is excreted into breast milk with M/P ratio approximately 0.3-0.5; infant exposure is low but may cause bradycardia or sedation. The combination should be used with caution during breastfeeding; monitoring the infant for signs of hypotension, electrolyte imbalance, and sedation is recommended.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
During pregnancy, the pharmacokinetics of methyldopa and hydrochlorothiazide may be altered due to increased plasma volume and renal blood flow. Initial dosing should be based on maternal weight. Methyldopa: Dose may need to be increased in second and third trimesters due to increased clearance; maximum dose 2 g/day. Hydrochlorothiazide: Avoid use in pregnancy due to risks; if absolutely necessary, dose should be minimized. Dose adjustments should be guided by maternal blood pressure response and fetal well-being.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Metatensin #4 is a combination of thiazide diuretic (hydrochlorothiazide 50 mg) and central alpha-agonist (methyldopa 500 mg). Use with caution in patients with renal impairment; monitor serum creatinine and electrolytes. Avoid abrupt discontinuation (risk of rebound hypertension). May cause positive Coombs test and hemolytic anemia (rare). Dose adjustment required in renal failure (Cr Cl <30 m L/min).
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Rise slowly from sitting or lying positions to prevent dizziness.,Avoid excessive sweating or dehydration; drink adequate fluids unless fluid-restricted.,Report unusual tiredness, fever, dark urine, yellowing of eyes/skin, or easy bruising/bleeding.,May increase blood sugar; monitor if diabetic.,Avoid alcohol, which can increase dizziness and drowsiness.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METATENSIN #4 vs ALDORIL 25, answered by our medical review team.
METATENSIN #4 is a Antihypertensive Combination that works by Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing c GMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METATENSIN #4 and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METATENSIN #4 is: 2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METATENSIN #4 and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METATENSIN #4 is classified as Category C. METATENSIN #4 (combination of hydrochlorothiazide 50 mg and methyldopa 250 mg per tablet) carries teratogenic risks primarily due to hydrochlorothiazide. First trimester: Thiazide . ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.